Job Information
- Organisation/Company
- The Netherlands Cancer Institute
- Research Field
- Medical sciencesPhysics
- Researcher Profile
- Recognised Researcher (R2)
- Country
- Netherlands
- Application Deadline
- Type of Contract
- Temporary
- Job Status
- Not Applicable
- Hours Per Week
- 36.0
- Is the job funded through the EU Research Framework Programme?
- Not funded by an EU programme
- Is the Job related to staff position within a Research Infrastructure?
- No
Offer Description
Project information
The Peeper lab uses functional oncogenomic and other advanced technology to combat immunotherapy resistance. The introduction of immune checkpoint antibodies and other therapies like TIL and CAR-T cells has been clinically transformative.
However, most patients fail to respond (durably), often because of upfront or acquired resistance. Several resistance mechanisms have been described, including tumor cell-intrinsic and T cell-dependent ones. To develop therapeutic solutions, it is imperative that we understand the underlying mechanisms. Here, we focus on a therapeutic strategy to break tumor cell-intrinsic immune resistance.
We have recently uncovered a critical and conserved mechanism of tumor cell-intrinsic resistance involving TNF-mediated survival signaling. By genetic screening, we discovered that ablation of TRAF2, a key TNF signal transducer sharply lowered the tumor TNF cytotoxicity threshold, thereby augmenting tumor T cell- and ICB-impact in vitro and in preclinical murine models. Furthermore, loss of TRAF2 in patient tumors increases immune sensitivity, which was
independently confirmed in a large-scale genetic analysis of clinical specimens. In this project, we focus on a druggable target in this pathway that we have discovered, aiming to not only understand its mechanism of action but also to explore clinical translation.
For further information and applications, please visit:
https://www.nki.nl/research/research-groups/daniel-peeper/.
Requirements
An ambitious technician with mouse model experience.
We seek an enthusiastic and accurate animal technician. It is strictly necessary that you hold a license for working with laboratory animals (art. 6/9/12). You should also have expertise in immunology and/or molecular biology. You will be responsible for carrying out animal experiments in collaboration with researchers on this project. Furthermore, you will contribute to wet-lab experiments and some lab management tasks. Proficiency in English and good communicative
skills are important requirements, as is a team player mentality.
Additional Information
The vacancy is available this Fall.
You will be employed for a minimum period of 2 years, with the possibility for extension. The gross salary per month can range from €2.832,- to €3.824 ,- (salary scale 45 according to the Collective Labour Agreement General Hospitals based on proven qualifications). In addition, you will receive 8,33% holiday pay and end-of-year bonus (8,33%).
Applications should include your CV, a motivation letter and references. Apply by the application button.
Select reading
- Zhang et al, RNF31 inhibition sensitizes tumors to bystander killing by innate and adaptive immune cells, Cell Reports Medicine 2022
- Apriamashvili et al, Ubiquitin ligase STUB1 destabilizes IFNγ-receptor complex to suppress tumor IFNγ signaling, Nature Comm 2022
- Vredevoogd et al, The (re)discovery of tumor-intrinsic determinants of immune sensitivity by functional genetic screens, IOTech 2022
- Vredevoogd et al., Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold, Cell 2019
The NKI values diversity and is committed to creating an inclusive work environment that stimulates the best in each individual. Applications of all individuals are welcomed regardless of age, ancestry, religion, disability, distance from the labor market, sexual orientation or gender identity.
Applications should include your CV, a motivation letter and references. Apply by the application button.
For more information please contact:
- Mylene van der Velden: m.vd.velden@nki.nl
- Daniel Peeper (Group leader): d.peeper@nki.nl
Select reading
- Zhang et al, RNF31 inhibition sensitizes tumors to bystander killing by innate and adaptive immune cells, Cell Reports Medicine 2022
- Apriamashvili et al, Ubiquitin ligase STUB1 destabilizes IFNγ-receptor complex to suppress tumor IFNγ signaling, Nature Comm 2022
- Vredevoogd et al, The (re)discovery of tumor-intrinsic determinants of immune sensitivity by functional genetic screens, IOTech 2022
- Vredevoogd et al., Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold, Cell 2019
The NKI values diversity and is committed to creating an inclusive work environment that stimulates the best in each individual. Applications of all individuals are welcomed regardless of age, ancestry, religion, disability, distance from the labor market, sexual orientation or gender identity.
- Website for additional job details
Work Location(s)
- Number of offers available
- 1
- Company/Institute
- The Netherlands Cancer Institute (NKI)
- Country
- Netherlands
- City
- Amsterdam
- Postal Code
- 1066 CX
- Street
- Plesmanlaan 121
- Geofield
Where to apply
- Website
Contact
- City
- Amsterdam
- Website
- Street
- Plesmanlaan 121
- Postal Code
- 1066 CX